Journal
ACTA PSYCHIATRICA SCANDINAVICA
Volume 125, Issue 1, Pages 45-53Publisher
WILEY
DOI: 10.1111/j.1600-0447.2011.01763.x
Keywords
psychosis; cannabis; prodromal; age at onset
Categories
Funding
- Eli Lilly
- Janssen-Cilag Pharmaceuticals
- AstraZeneca BV
- Pfizer
- Bristol-Myers Squib
- Janssen Pharmaceuticals
- Johnson and Johnson Pharmaceuticals
- European Commission [QLG4-CT-2001-01081]
- Health Research Council of the Netherlands [2630.0001]
- Social Insurance Institution of Finland [Dnro 12-26-2006]
- Medical Faculty of Cologne
Ask authors/readers for more resources
Objective: Numerous studies have found a robust association between cannabis use and the onset of psychosis. Nevertheless, the relationship between cannabis use and the onset of early ( or, in retrospect, prodromal) symptoms of psychosis remains unclear. The study focused on investigating the relationship between cannabis use and early and high-risk symptoms in subjects at clinical high risk for psychosis. Method: Prospective multicenter, naturalistic field study with an 18-month follow-up period in 245 help-seeking individuals clinically at high risk. The Composite International Diagnostic Interview was used to assess their cannabis use. Age at onset of high risk or certain early symptoms was assessed retrospectively with the Interview for the Retrospective Assessment of the Onset of Schizophrenia. Results: Younger age at onset of cannabis use or a cannabis use disorder was significantly related to younger age at onset of six symptoms (0.33 < r(s) < 0.83, 0.004 < P < 0.001). Onset of cannabis use preceded symptoms in most participants. Conclusion: Our results provide support that cannabis use plays an important role in the development of psychosis in vulnerable individuals. Cannabis use in early adolescence should be discouraged.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available